Walleye Capital LLC Has $14.08 Million Stock Holdings in ANI Pharmaceuticals, Inc. $ANIP

Walleye Capital LLC increased its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 56.1% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 183,075 shares of the specialty pharmaceutical company’s stock after purchasing an additional 65,768 shares during the quarter. Walleye Capital LLC’s holdings in ANI Pharmaceuticals were worth $14,078,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of ANIP. Globeflex Capital L P lifted its stake in ANI Pharmaceuticals by 52.0% in the 1st quarter. Globeflex Capital L P now owns 84,145 shares of the specialty pharmaceutical company’s stock worth $6,471,000 after acquiring an additional 28,784 shares in the last quarter. Cetera Investment Advisers purchased a new position in ANI Pharmaceuticals during the 1st quarter valued at about $373,000. First Trust Advisors LP grew its stake in ANI Pharmaceuticals by 12.8% during the 1st quarter. First Trust Advisors LP now owns 99,747 shares of the specialty pharmaceutical company’s stock valued at $7,671,000 after acquiring an additional 11,346 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in ANI Pharmaceuticals by 8.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 531,190 shares of the specialty pharmaceutical company’s stock valued at $40,843,000 after acquiring an additional 43,523 shares in the last quarter. Finally, KBC Group NV acquired a new position in shares of ANI Pharmaceuticals in the 1st quarter valued at about $28,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock opened at $77.61 on Thursday. ANI Pharmaceuticals, Inc. has a fifty-two week low of $62.60 and a fifty-two week high of $99.50. The stock’s 50-day moving average is $81.28 and its two-hundred day moving average is $79.48. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52. The firm has a market cap of $1.77 billion, a P/E ratio of 19.65 and a beta of 0.43.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.77. The business had revenue of $237.46 million during the quarter, compared to analyst estimates of $207.63 million. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The firm’s revenue was up 20.5% on a year-over-year basis. During the same period in the previous year, the company earned $1.70 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Analysts predict that ANI Pharmaceuticals, Inc. will post 8.03 earnings per share for the current fiscal year.

Insider Activity

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 3,313 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $86.00, for a total value of $284,918.00. Following the completion of the sale, the chief financial officer directly owned 177,543 shares in the company, valued at $15,268,698. The trade was a 1.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Patrick D. Walsh sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $80.63, for a total transaction of $806,300.00. Following the completion of the sale, the director directly owned 38,432 shares of the company’s stock, valued at $3,098,772.16. This represents a 20.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 85,179 shares of company stock valued at $6,722,596. 8.10% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

ANIP has been the subject of a number of research analyst reports. Canaccord Genuity Group initiated coverage on shares of ANI Pharmaceuticals in a research report on Thursday, July 16th. They issued a “hold” rating and a $91.00 price target for the company. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Weiss Ratings upgraded shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, June 23rd. Guggenheim reiterated a “buy” rating and issued a $124.00 target price on shares of ANI Pharmaceuticals in a research report on Friday, July 10th. Finally, Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Six equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, ANI Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $105.00.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.